C Ray Therapeutics Bolsters Global Radiopharma Credentials With AAALAC Accreditation and Regulatory Strategy Focus

C Ray Therapeutics is a China-based radiopharmaceutical CRDMO, and this weekly recap highlights notable strategic and operational developments. The company secured AAALAC International Full Accreditation for its Chengdu animal care program and used industry forums to refine its positioning in early-stage radiopharma development.

The AAALAC credential covers a 28,000-square-meter integrated facility that combines accredited preclinical services with cGMP manufacturing under China’s Class A Radiation Safety License. C Ray can work with more than 30 radioisotopes, including Actinium-225, and reports over 70 delivered projects, 16 investigator-initiated trials, and multiple programs now in Phase III.

Management presents the accreditation as a key enabler for Western-grade regulatory submissions and a differentiator for global partners focused on ethics and data integrity in China-based studies. By linking AAALAC-compliant research with an investigator-initiated trial framework, the company aims to help clients compress first-in-human timelines to roughly six to nine months.

C Ray emphasized its role as a specialized radiopharma CRDMO supporting programs from target validation through IND-enabling work and clinical supply. Its platform has supported five programs through IND or IND-enabling stages and three clinical supply programs, with two to three candidates reported at Phase III, underscoring growing depth in its service portfolio.

The company also participated in the TRP Summit 2026 in Boston, where its senior business development leader joined a panel on preclinical strategy for Phase Zero and first-in-human radiopharmaceutical trials. Public commentary from the summit stressed pairing therapeutic radiopharmaceuticals with companion diagnostics and warned against over-reliance on rodent biodistribution data.

C Ray discussed theragnostic design trade-offs, noting that separate diagnostic and therapeutic agents may sometimes be more effective than a single dual-purpose molecule. The firm highlighted that using a common molecular backbone can appeal to regulators but may be limited by differing biological and imaging requirements, with implications for timelines and capital allocation.

The company further underscored nuanced U.S. FDA expectations for overseas investigator-initiated trial data, citing both rejected and accepted cases based on data quality and documentation. High-quality safety data from China-based studies have, in some examples, enabled acceptance and avoided duplicative trials, potentially saving about 12 months in development.

Taken together, these developments indicate that C Ray is strengthening both its operational infrastructure and thought-leadership role in radiopharmaceutical development. While no new revenue or funding metrics were disclosed beyond the previously raised $187 million, the AAALAC accreditation and regulatory strategy focus could support future partnerships and reinforce its long-term competitiveness in the global radiopharma services market.